The company has designed the system to optimally implant with its robotic-assisted technology, the Navio system.

Blue Belt Technologies president and CEO Eric Timko said: "Receiving CE Mark for Stride is an important milestone for Blue Belt as we continue to expand our commercial footprint outside the US."

"The Stride implant has been specially designed to pair with our Navio robotic-assisted surgical technology which has been in use clinically since 2012."

According to the company, Stride is currently available to treat both medial and lateral unicompartmental knee replacement.

Stride received approval from the US Food and Drug Administration (FDA) for Stride in June 2014, while available commercially since October 2014.

The CE mark approval allows the company to market the system, along with its Navio Surgical System, in certain markets outside the US.

Blue Belt noted that Navio system will continue to support multiple leading unicondylar and patellofemoral knee systems and remain an open-platform technology.

The company develops and markets surgical instruments for initial use in orthopedic procedures, as well as for other surgical specialties, including neurosurgery, spinal and otolaryngology.

Image: Human Knee. Photo: courtesy of cooldesign/